We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The software can be “customized to meet the needs of each lab’s users while maintaining the tight process controls needed for a regulated application,” the company said. Read More
LumiraDx said it has the manufacturing capacity to “enable rapid, high-sensitivity mass screening programs” in schools, events, travel and other settings. Read More
Guilford, Conn.-based Detect’s test is a molecular in vitro diagnostic test for the qualitative detection of nucleic acid from the coronavirus SARS-CoV-2, which causes COVID-19. Read More
In tests in clinical centers, the system achieved more than 90 percent accuracy in a drug susceptibility assessment of 20 antibiotics, the company said. Read More